Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436851 | 0.85 | AHR (0.38) | ALDH1A1AHRCYP2A6GAANPC1 | |
| SCHEMBL16970612 | 0.81 | ALDH1A1 (0.37) | MAPK1ALDH1A1AHRCYP2A6GAA | |
| SCHEMBL7398986 | 0.80 | HPGD (0.37) | ALDH1A1POLBMEN1NPC1RAB9A | |
| SCHEMBL1116582 | 0.80 | GABRP (0.38) | ALDH1A1MAOBGCGRMAPK14MEN1 | |
| SCHEMBL436626 | 0.80 | AHR (0.34) | AHRCYP2A6GAAMGAMSI | |
| SCHEMBL8506859 | 0.79 | GABRP (0.42) | ALDH1A1GAAMAOBGCGRMAPK14 | |
| SCHEMBL1116711 | 0.79 | CYP1A2 (0.41) | MAPK1ALDH1A1CYP2A6POLBMEN1 | |
| SCHEMBL2431368 | 0.78 | NOTUM (0.34) | MAOB | |
| SCHEMBL15067608 | 0.78 | TP53 (0.35) | ALDH1A1AHRCYP2A6TP53CYP3A4 | |
| SCHEMBL4062697 | 0.77 | KIF11 (0.41) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155689-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-07-08 | — | — | EP | claimed |
| EP-2155689-B1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-7479575-B2 | Method for preparing para-phenyl alkynyl benzaldehydes | LABORATOIRES SERONO SA (CH) | 2009-01-20 | — | — | US | disclosed |
| US-20080108849-A1 | Method For Preparing Para-Phenyl Alkynyl Benzaldehydes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-05-08 | — | — | US | disclosed |
| EP-1675813-B1 | METHOD FOR PREPARING PARA-PHENYL ALKYNYL BENZALDEHYDES | SERONO LAB (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-08-10 | — | — | US | disclosed |
| EP-1675813-A1 | METHOD FOR PREPARING PARA-PHENYL ALKYNYL BENZALDEHYDES | Applied Research Systems ARS Holding N.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
| US-7053101-B2 | 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JORDAN ALFONZO | 2006-05-30 | — | — | US | disclosed |
| WO-2005037758-A1 | METHOD FOR PREPARING PARA-PHENYL ALKYNYL BENZALDEHYDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-04-28 | — | — | WO | disclosed |
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JORDAN ALFONZO (US) | 2005-01-06 | — | — | US | disclosed |
| US-6777421-B2 | TREATING A CONDITION SELECTED FROM THE GROUP CONSISTING OF ANXIETY, DEPRESSION, SUBSTANCE ABUSE, NEUROPATHIC PAIN, ACUTE PAIN, MIGRAINE, ASTHMA, COUGH AND IMPROVED COGNITION, IN A SUBJECT IN NEED THEREOF COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1392687-A1 | 1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-12 | — | — | US | disclosed |
| WO-2002083673-A1 | 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0555058-B1 | (Oxo)sulfonium complex, polymerizable composition containing the complex, and method of polymerizing composition | TOYO INK MFG CO (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004154-A1 | 1,2,8-Triazaspiro{decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | OPRL1, CALCRL, OPRK1 | MAPK1 976/4885ALDH1A1 359/4885AHR 2619/4885 |
| US-20080108849-A1 | Method For Preparing Para-Phenyl Alkynyl Benzaldehydes | TNNC1, CPT1B, MUSK | MAPK1 1361/4885ALDH1A1 200/4885AHR 203/4885 |
| US-20060178390-A1 | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, OPRK1, CALCRL | MAPK1 545/4885ALDH1A1 387/4885AHR 2834/4885 |
| US-20030109539-A1 | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, GPR4, GPR174 | MAPK1 602/4885ALDH1A1 492/4885AHR 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.